Amgen has announced plans to invest more than $600 million in a cutting-edge center for science and innovation at its global headquarters in Thousand Oaks, California. The new facility is designed to foster collaboration among researchers, engineers, and scientists to accelerate the discovery of next-generation therapeutics targeting serious diseases.
The state-of-the-art building will feature advanced automation and digital technologies, providing scientists with enhanced tools and an environment geared toward driving breakthroughs in biotechnology.
This investment reflects Amgen’s strong commitment to U.S. innovation and manufacturing. Since the 2017 Tax Cuts and Jobs Act (TCJA), the company has invested over $40 billion in manufacturing and R&D, including more than $5 billion in direct U.S. capital expenditures. The recent One Big Beautiful Bill Act of 2025 further supports Amgen’s ability to invest domestically in scientific and manufacturing excellence.
Robert A. Bradway, Amgen’s chairman and CEO, emphasized that the new center will empower scientists to lead the next era of discovery and improve human health.
Construction is slated to begin in the third quarter of 2025 and is expected to create hundreds of jobs in the U.S. Amgen has been based in Thousand Oaks for over 45 years, contributing to the greater Los Angeles region.
This announcement follows Amgen’s recent investments, including a $900 million expansion of its Ohio manufacturing facility and a $1 billion project to build a second plant in Holly Springs, North Carolina.